Government-Owned Inventions; Availability for Licensing, 13352-13354 [2013-04443]
Download as PDF
<![CDATA[
13352
Federal Register / Vol. 78, No. 39 / Wednesday, February 27, 2013 / Notices
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Proposed Collection: Title: Clinical
Mythteries: A Video Game About
Clinical Trials. Type of Information
Collection Request: NEW. Need and Use
of Information Collection: New England
Research Institutes as a contractor for
the National Heart Lung and Blood
Institute is planning to create an
engaging, informational ‘‘serious video
game’’ for adolescents about clinical
studies which: (1) Incorporates core
learning objectives; and (2) dispels
misconceptions. Two types of
information collection are planned:
• Usability testing to understand gameplay/usability. This information will be
collected by focus group and will be
digitally recorded 90 minute groups.
• A pre/post randomized trial to
measure change in knowledge. This
information will be collected
electronically through on-line
questionnaire.
The game will be incorporated with a
larger initiative to provide information
about clinical research (https://
www.nhlbi.nih.gov/
childrenandclinicalstudies/index.php).
Frequency of Response: Once. Affected
Public: Individuals. Type of
Respondents: Adolescents—aged 8–14.
Estimated
number of
respondents
The annual reporting burden is as
follows: Estimated Number of
Respondents: 280; Estimated Number of
Responses per Respondent: 1; Average
Burden Hours per Response: Wave 1—
90/60 (1.5 hours), Wave 2—80/60 (1.33
hours); and Estimated Total Annual
Burden Hours Requested: 378. The
annualized cost to respondents is
estimated at: $3,783. There are no
Capital Costs to report. The Operating
Costs to collect this information is
estimated at $42,425.00.
Note: The following table is acceptable for
the Respondent and Burden Estimate
information, if appropriate, instead of the
text as shown above.
Estimated
number of
responses per
respondent
Average
burden hours
per response
Estimated total
annual burden
hours
requested
Form name
Type of respondents
Qualtative Focus Group Discussion Guide
and screener.
Screen pre post eval ...................................
Adolescents—Wave one
30
1
90/60 (1.5 hours) ..
45
Adolescents—Wave two
250
1
80/60 (1.33 hours)
333
.........................................
280
........................
...............................
378
erowe on DSK2VPTVN1PROD with NOTICES
Total .....................................................
Request For Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Victoria
Pemberton, RNC, MS, CCRC, National
Heart, Lung and Blood Institute, 6701
VerDate Mar<15>2010
15:18 Feb 26, 2013
Jkt 229001
Rockledge Drive, Rm. 8109, Bethesda,
MD 20892, or call non-toll-free number
(301) 435–0510 or Email your request,
including your address to:
pembertonv@mail.nih.gov
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
Dated: February 8, 2013.
Michael Lauer,
Director, Division of Cardiovascular Diseases,
National Heart, Lung, and Blood Institute,
NIH.
Dated: February 12, 2013.
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2013–04547 Filed 2–26–13; 8:45 am]
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
BILLING CODE 4140–01–P
Java Software for Investigational Drug
Clinical Research
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Description of Technology: A Java
based software application available for
academic use and on a royalty-bearing
basis for commercial licensing. The
Investigational Drug Management
System (IDMS) supports the operational
needs of the investigation drug section
of a pharmacy providing inventory
management functions which fulfill the
recordkeeping requirements defined in
the Code of Federal Regulations related
to the storage, labeling, handling, and
dispensing of investigational drugs. The
internet/browser based application
interfaces with the Computerized
Provider Order Entry (CPOE) system for
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
E:\FR\FM\27FEN1.SGM
27FEN1
Federal Register / Vol. 78, No. 39 / Wednesday, February 27, 2013 / Notices
erowe on DSK2VPTVN1PROD with NOTICES
tracking patients and prescriptions for
investigational drugs. The IDMS
supports the prescription filling process
by capturing real-time data during the
dispensing activity where automated
safety checks are performed, ensuring
the ‘‘five rights’’ of medication use are
satisfied. The system supports
randomized double-blind clinical trials
by generating complex, multi-tiered
randomization schemes that produce
patient-specific treatment assignments
along with industry standard labels
containing barcodes. IDMS serves as the
book of record providing end-to-end
traceability for the receipt of raw
materials from their source to the
dispensing of finished pharmaceutical
dosage forms to patients.
Potential Commercial Applications:
• Clinical data management
• Clinical Trials
• Investigational new drug trials
Competitive Advantages:
• Web based
• User friendly
• Data portability
• Randomization tables
Development Stage:
• Prototype
• Clinical
Inventors: Richard O. DeCederfelt,
George J. Grimes, Stephen M. Bergstrom,
Jon W. McKeeby (all of NIH–CC).
Intellectual Property: HHS Reference
No. E–063–2013/0—Research Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Software To Improve the Quality of
Microscopy Images
Description of Technology: Available
for licensing and commercial use is
software based on an iterative
deconvolution procedure that recovers
images that have been blurred by a
known point spread function. The
software provides superior results when
multiple independent observations of
the same specimen are obtained. An
example of such observations might be
the multiple views of a specimen
collected by a selective illumination
plane microscope (SPIM). By using the
blurring function and observations (raw
images) corresponding to each view in
sequential order through the iteration
loop, the resulting output contains
higher resolution, contrast, and signal
than would result if any single
observation alone was used, or if the
output from single deconvolution
operations on each image are combined,
e.g. by averaging. In its current form, the
software has been tested on the
VerDate Mar<15>2010
15:18 Feb 26, 2013
Jkt 229001
Richardson-Lucy deconvolution (RLD)
procedure. Preliminary data indicate
that the algorithm provides an isotropic
resolution of 350 nm, greatly improving
the raw data (lateral resolution 0.5
microns, axial resolution 1.5 microns)
on nematode embryos. In vivo data
illustrating the power of the algorithm
are available upon request.
Potential Commercial Applications:
• Image Resolution
• Sub-micron microscopy
Competitive Advantages:
• Enables isotopic resolution
• Iterative deconvolution algorithm that
can readily be applied to SPIM
datasets
Development Stage:
• Prototype
• In vitro data available
• In vivo data available (animal)
Inventors: Hari Shroff, Andrew York,
Yicong Wu (all of NIBIB).
Publications:
1. Swoger J, et al. Multi-view image fusion
improves resolution in threedimensional microscopy. Opt Express.
2007 Jun 25;15(13):8029–42. [PMID
19547131]
2. Verveer PJ, et al. High-resolution threedimensional imaging of large specimens
with light sheet-based microscopy. Nat
Methods. 2007 Apr;4(4):311–3. [PMID
17339847]
Intellectual Property: HHS Reference
No. E–062–2013/0—Software Tool.
Patent protection is not being pursued
for this technology.
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NIBIB Section on High Resolution
Optical Imaging is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize our algorithm, especially
with respect to multiview microscopes.
For collaboration opportunities, please
contact Hari Shroff at
hari.schroff@nih.gov.
Background-Free Fluorescent
Nanodiamond Imaging
Description of Technology: Available
for licensing and commercial
development are intellectual property
rights covering a method of imaging a
biological specimen (e.g., human tissue)
using fluorescent nanodiamonds
implanted into the subject of interest,
applying a magnetic field to said subject
and producing a resultant image by a
net juxtaposition of a second acquired
image. This process suppresses the
background and permits selective
imaging of the nanodiamonds in the
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
13353
presence of background fluorescence
that exceeds the signal from the
nanodiamonds. Another aspect of the
invention provides an imaging method
in which the resulting image is acquired
by applying time-varying magnetic
fields using one or more secondary
image averaged against the first. The
technique relies on imposing a small
(∼100 Gauss) magnetic field on the
sample of interest during optical
imaging combined with post-processing
of the acquired images to remove the
background. This technology can
readily be added onto any commercial
optical imaging platform to achieve
background-free images of the
nanodiamonds in a biological specimen.
Potential Commercial Applications:
• In vitro and in vivo optical imaging
and diagnostics
• MRI imaging
Competitive Advantages:
• Improved resolution through
composite imagery
• Background elimination
• Indefinite tracking due to the
exceptional stability of the fluorescent
nanodiamonds
• Wide excitation band (∼500–600 nm)
• Broad-band Near IR emission (600–
700 nm)
• Nanodiamonds are stable in aqueous
solution
• In related technologies we have
developed a method to specifically
coat and functionalize nanodiamonds
for targeting and labeling applications
Development Stage:
• Prototype
• In vitro data available
• In vivo data available (animal)
Inventors: Susanta Sarkar, Ambika
Bumb, Keir Neuman (all of NHLBI).
Intellectual Property: HHS Reference
No. E–261–2012/0—US Provisional
Application No. 61/711,702 filed 09 Oct
2012.
Related Technology: HHS Reference
No. E–175–2012/0—US Provisional
Application No. 61/672,996 filed 18 Jul
2012, ‘‘Method of Preparing Silicacoated Nanodiamonds.’’
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NHLBI Laboratory of Single
Molecule Biophysics is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize background-free imaging
of fluorescent nanodiamonds for in vivo
and in vitro applications. For
collaboration opportunities, please
contact Keir C. Neuman, Ph.D. at
neumankc@mail.nih.gov or 301–496–
3376.
E:\FR\FM\27FEN1.SGM
27FEN1
13354
Federal Register / Vol. 78, No. 39 / Wednesday, February 27, 2013 / Notices
Silica-Coated Nanodiamonds for
Imaging and the Delivery of
Therapeutic Agents
Description of Technology: NIH
investigators invented a robust and
easily implemented method of
synthesizing silica-coated
nanodiamonds for imaging and
therapeutic applications. A patent estate
covering these methods is offered for
licensing to commercial entities. The
method generally includes coating
nanodiamonds with a silica precursor,
e.g., tetraethylorthosilicate (TEOS),
inside liposomes. The liposomes are
then removed to yield a final product
that is stable, monodisperse, and easy to
functionalize.
Potential Commercial Applications:
• Imaging
• Drug delivery
Competitive Advantages:
• Small size
• Physiologically inert carrier
• Monodisperse
• Stable in aqueous solution
• Readily functionalized
Development Stage: Prototype.
Inventors: Ambika Bumb (NHLBI),
Susanta Kumar Sarkar (NHLBI), Keir
Neuman (NHLBI), Martin Brechbiel
(NCI).
Publications:
erowe on DSK2VPTVN1PROD with NOTICES
1. Yu SJ, et al. Bright fluorescent
nanodiamonds: no photobleaching and
low cytotoxicity. J Am Chem Soc. 2005
Dec 21;127(50):17604–5. [PMID
16351080]
2. Wilson RM. Nanodiamonds are promising
quantum probes of living cells. Phys
Today 2011 Aug;64(8):17. [doi 10.1063/
PT.3.1204]
3. Chow EK, et al. Nanodiamond therapeutic
delivery agents mediate enhanced
chemoresistant tumor treatment. Sci
Transl Med. 2011 Mar 9;3(73):73ra21.
[PMID 21389265]
4. Krueger A. New carbon materials:
biological applications of functionalized
nanodiamond materials. Chemistry
2008;14(5):1382–90. [PMID 18033700]
Intellectual Property: HHS Reference
No. E–175–2012/0—US Provisional
Application No. 61/672,996 filed 18 Jul
2012.
Related Technology: HHS Reference
No. E–261–2012/0—US Provisional
Application No. 61/711,702 filed 09 Oct
2012, ‘‘Imaging Methods and ComputerReadable Media for Background-Free
imaging of Fluorescent Nanodiamonds.’’
Licensing Contact: Michael
Shmilovich; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NHLBI Laboratory of Single
Molecule Biophysics is seeking
statements of capability or interest from
VerDate Mar<15>2010
15:18 Feb 26, 2013
Jkt 229001
parties interested in collaborative
research to further develop, evaluate or
commercialize fluorescent
nanodiamonds for use as in vivo and in
vitro optical tracking probes. For
collaboration opportunities, please
contact Keir C. Neuman, Ph.D. at
neumankc@mail.nih.gov or 301–496–
3376.
Dated February 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–04443 Filed 2–26–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Chimeric Antigen Receptors to CD22 for
Treating Hematological Cancers
Description of Technology: Chimeric
antigen receptors (CARs) are hybrid
proteins consisting of an antibody
binding fragment fused to protein
signaling domains that cause T-cells
which express the CAR to become
cytotoxic. Once activated, these
cytotoxic T-cells can selectively
eliminate the cells which they recognize
via the antibody binding fragment of the
CAR. Thus, by engineering a T-cell to
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
express a CAR that is specific for a
certain cell surface protein, it is possible
to selectively target those cells for
destruction. This is a promising new
therapeutic approach known as
adoptive cell therapy.
CD22 is a cell surface protein that is
expressed on a large number of B-cell
lineage hematological cancers, such as
leukemia and lymphoma. Several
promising therapies are being developed
which target CD22, including
therapeutic antibodies and
immunotoxins. This technology
concerns the use of a high affinity
antibody binding fragment to CD22
(known as m971), as the targeting
moiety of a CAR. The resulting CAR can
be used in adoptive cell therapy
treatment for cancer.
Potential Commercial Applications:
• Treatment of diseases associated with
increased or preferential expression of
CD22
• Specific diseases include
hematological cancers such as chronic
lymphocytic leukemia (CLL), hairy
cell leukemia (HCL) and pediatric
acute lymphoblastic leukemia (ALL)
Competitive Advantages:
• High affinity of the m971 antibody
binding fragment increases the
likelihood of successful targeting
• Targeted therapy decreases nonspecific killing of healthy, essential
cells, resulting in fewer non-specific
side-effects and healthier patients
• Hematological cancers are susceptible
to cytotoxic T-cells for treating
because they are present in the
bloodstream
• Expression of CD22 only on mature
cells allows the avoidance of stem cell
elimination during treatment
Development Stage: Pre-clinical.
Inventors: Rimas J. Orentas et al.
(NCI).
Intellectual Property: HHS Reference
No. E–291–2012/0—US Provisional
Application No. 61/717,960 filed 24 Oct
2012.
Related Technology: HHS Reference
No. E–080–2008/0—U.S. Patent
Application No. 12/934,214 filed 23 Sep
2010.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Modified Peptide Nucleic Acids (PNAs)
for Detection of DNA or RNA and
Identification of a Disease or Pathogen
Description of Technology: The NIH
announces a novel method for fast,
simple, and accurate detection of
nucleic acids outside the modern
laboratory. Nucleic acid testing is highly
specific and often provides definitive
E:\FR\FM\27FEN1.SGM
27FEN1
]]>Agencies
[Federal Register Volume 78, Number 39 (Wednesday, February 27, 2013)]
[Notices]
[Pages 13352-13354]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-04443]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Java Software for Investigational Drug Clinical Research
Description of Technology: A Java based software application
available for academic use and on a royalty-bearing basis for
commercial licensing. The Investigational Drug Management System (IDMS)
supports the operational needs of the investigation drug section of a
pharmacy providing inventory management functions which fulfill the
recordkeeping requirements defined in the Code of Federal Regulations
related to the storage, labeling, handling, and dispensing of
investigational drugs. The internet/browser based application
interfaces with the Computerized Provider Order Entry (CPOE) system for
[[Page 13353]]
tracking patients and prescriptions for investigational drugs. The IDMS
supports the prescription filling process by capturing real-time data
during the dispensing activity where automated safety checks are
performed, ensuring the ``five rights'' of medication use are
satisfied. The system supports randomized double-blind clinical trials
by generating complex, multi-tiered randomization schemes that produce
patient-specific treatment assignments along with industry standard
labels containing barcodes. IDMS serves as the book of record providing
end-to-end traceability for the receipt of raw materials from their
source to the dispensing of finished pharmaceutical dosage forms to
patients.
Potential Commercial Applications:
Clinical data management
Clinical Trials
Investigational new drug trials
Competitive Advantages:
Web based
User friendly
Data portability
Randomization tables
Development Stage:
Prototype
Clinical
Inventors: Richard O. DeCederfelt, George J. Grimes, Stephen M.
Bergstrom, Jon W. McKeeby (all of NIH-CC).
Intellectual Property: HHS Reference No. E-063-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Software To Improve the Quality of Microscopy Images
Description of Technology: Available for licensing and commercial
use is software based on an iterative deconvolution procedure that
recovers images that have been blurred by a known point spread
function. The software provides superior results when multiple
independent observations of the same specimen are obtained. An example
of such observations might be the multiple views of a specimen
collected by a selective illumination plane microscope (SPIM). By using
the blurring function and observations (raw images) corresponding to
each view in sequential order through the iteration loop, the resulting
output contains higher resolution, contrast, and signal than would
result if any single observation alone was used, or if the output from
single deconvolution operations on each image are combined, e.g. by
averaging. In its current form, the software has been tested on the
Richardson-Lucy deconvolution (RLD) procedure. Preliminary data
indicate that the algorithm provides an isotropic resolution of 350 nm,
greatly improving the raw data (lateral resolution 0.5 microns, axial
resolution 1.5 microns) on nematode embryos. In vivo data illustrating
the power of the algorithm are available upon request.
Potential Commercial Applications:
Image Resolution
Sub-micron microscopy
Competitive Advantages:
Enables isotopic resolution
Iterative deconvolution algorithm that can readily be applied
to SPIM datasets
Development Stage:
Prototype
In vitro data available
In vivo data available (animal)
Inventors: Hari Shroff, Andrew York, Yicong Wu (all of NIBIB).
Publications:
1. Swoger J, et al. Multi-view image fusion improves resolution in
three-dimensional microscopy. Opt Express. 2007 Jun 25;15(13):8029-
42. [PMID 19547131]
2. Verveer PJ, et al. High-resolution three-dimensional imaging of
large specimens with light sheet-based microscopy. Nat Methods. 2007
Apr;4(4):311-3. [PMID 17339847]
Intellectual Property: HHS Reference No. E-062-2013/0--Software
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIBIB Section on High
Resolution Optical Imaging is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize our algorithm, especially with
respect to multiview microscopes. For collaboration opportunities,
please contact Hari Shroff at hari.schroff@nih.gov.
Background-Free Fluorescent Nanodiamond Imaging
Description of Technology: Available for licensing and commercial
development are intellectual property rights covering a method of
imaging a biological specimen (e.g., human tissue) using fluorescent
nanodiamonds implanted into the subject of interest, applying a
magnetic field to said subject and producing a resultant image by a net
juxtaposition of a second acquired image. This process suppresses the
background and permits selective imaging of the nanodiamonds in the
presence of background fluorescence that exceeds the signal from the
nanodiamonds. Another aspect of the invention provides an imaging
method in which the resulting image is acquired by applying time-
varying magnetic fields using one or more secondary image averaged
against the first. The technique relies on imposing a small (~100
Gauss) magnetic field on the sample of interest during optical imaging
combined with post-processing of the acquired images to remove the
background. This technology can readily be added onto any commercial
optical imaging platform to achieve background-free images of the
nanodiamonds in a biological specimen.
Potential Commercial Applications:
In vitro and in vivo optical imaging and diagnostics
MRI imaging
Competitive Advantages:
Improved resolution through composite imagery
Background elimination
Indefinite tracking due to the exceptional stability of the
fluorescent nanodiamonds
Wide excitation band (~500-600 nm)
Broad-band Near IR emission (600-700 nm)
Nanodiamonds are stable in aqueous solution
In related technologies we have developed a method to
specifically coat and functionalize nanodiamonds for targeting and
labeling applications
Development Stage:
Prototype
In vitro data available
In vivo data available (animal)
Inventors: Susanta Sarkar, Ambika Bumb, Keir Neuman (all of NHLBI).
Intellectual Property: HHS Reference No. E-261-2012/0--US
Provisional Application No. 61/711,702 filed 09 Oct 2012.
Related Technology: HHS Reference No. E-175-2012/0--US Provisional
Application No. 61/672,996 filed 18 Jul 2012, ``Method of Preparing
Silica-coated Nanodiamonds.''
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NHLBI Laboratory of Single
Molecule Biophysics is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize background-free imaging of fluorescent
nanodiamonds for in vivo and in vitro applications. For collaboration
opportunities, please contact Keir C. Neuman, Ph.D. at
neumankc@mail.nih.gov or 301-496-3376.
[[Page 13354]]
Silica-Coated Nanodiamonds for Imaging and the Delivery of Therapeutic
Agents
Description of Technology: NIH investigators invented a robust and
easily implemented method of synthesizing silica-coated nanodiamonds
for imaging and therapeutic applications. A patent estate covering
these methods is offered for licensing to commercial entities. The
method generally includes coating nanodiamonds with a silica precursor,
e.g., tetraethylorthosilicate (TEOS), inside liposomes. The liposomes
are then removed to yield a final product that is stable, monodisperse,
and easy to functionalize.
Potential Commercial Applications:
Imaging
Drug delivery
Competitive Advantages:
Small size
Physiologically inert carrier
Monodisperse
Stable in aqueous solution
Readily functionalized
Development Stage: Prototype.
Inventors: Ambika Bumb (NHLBI), Susanta Kumar Sarkar (NHLBI), Keir
Neuman (NHLBI), Martin Brechbiel (NCI).
Publications:
1. Yu SJ, et al. Bright fluorescent nanodiamonds: no photobleaching
and low cytotoxicity. J Am Chem Soc. 2005 Dec 21;127(50):17604-5.
[PMID 16351080]
2. Wilson RM. Nanodiamonds are promising quantum probes of living
cells. Phys Today 2011 Aug;64(8):17. [doi 10.1063/PT.3.1204]
3. Chow EK, et al. Nanodiamond therapeutic delivery agents mediate
enhanced chemoresistant tumor treatment. Sci Transl Med. 2011 Mar
9;3(73):73ra21. [PMID 21389265]
4. Krueger A. New carbon materials: biological applications of
functionalized nanodiamond materials. Chemistry 2008;14(5):1382-90.
[PMID 18033700]
Intellectual Property: HHS Reference No. E-175-2012/0--US
Provisional Application No. 61/672,996 filed 18 Jul 2012.
Related Technology: HHS Reference No. E-261-2012/0--US Provisional
Application No. 61/711,702 filed 09 Oct 2012, ``Imaging Methods and
Computer-Readable Media for Background-Free imaging of Fluorescent
Nanodiamonds.''
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NHLBI Laboratory of Single
Molecule Biophysics is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize fluorescent nanodiamonds for use as in vivo
and in vitro optical tracking probes. For collaboration opportunities,
please contact Keir C. Neuman, Ph.D. at neumankc@mail.nih.gov or 301-
496-3376.
Dated February 20, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-04443 Filed 2-26-13; 8:45 am]
BILLING CODE 4140-01-P
